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 Abstract 
Objectives: To establish sex differences in remodelling and outcome in aortic stenosis (AS) and 
their associations with biomarkers of myocardial fibrosis.   
Background: The remodelling response and timing of symptoms is highly variable in AS, and 
gender plays an important role.  
Methods: 174 patients (133 male, mean age 66.2 ± 13.3 years) with asymptomatic moderate to 
severe AS underwent comprehensive stress cardiac magnetic resonance (CMR) imaging, trans-
thoracic echocardiography (TTE) and biomarker analysis (MMP-2, 3, 7, 8 and 9, TIMP-1, 4, 
syndecan-1 and 4 and NT-proBNP), and were followed up at 6-monthly intervals. A primary 
endpoint was a composite of typical AS symptoms necessitating referral for AVR, 
cardiovascular death or major adverse cardiovascular events. 
Results: For a similar severity of AS, male patients demonstrated higher indexed LV volumes 
and mass, more concentric remodelling (higher LV mass/volume), a trend to more late 
gadolinium enhancement (LGE) (present in 51.1% male vs. 34.1% female, p=0.057) and higher 
extra-cellular volume index than female patients (13.27 [11.5, 17.0] vs. 11.53 [10.5, 13.5] ml/m2, 
p=0.017), with worse systolic and diastolic function and higher MMP-3 and syndecan-4 levels, 
whilst females had higher septal E/e’. Male sex was independently associated with indexed LV 
mass (β=13.32 (9.59-17.05), p<0.001). During median follow-up of 374 (IQR 351-498) days, a 
primary outcome, driven by spontaneous symptom onset, occurred in 21.8% of male and 43.9% 
of female patients (RR 0.50 (CI 0.31, 0.80), p=0.004). Measures of AS severity were associated 
with the primary outcome in both sexes, whereas NT-proBNP, MMP3 and mass/volume were 
only associated in males. 
Conclusions: In AS, females tolerate pressure overload with less concentric remodelling and 
myocardial fibrosis but are more likely to develop symptoms. This may be related to higher wall 
stress and filling pressures in females. 
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AVA(I): aortic valve area (index) 
AVR: aortic valve replacement 
CMR: cardiovascular magnetic resonance 
ECV: extracellular volume 
MPG: mean pressure gradient 
PWV: pulse wave velocity 
LGE: late gadolinium enhancement 
LV: left ventricle 
LVMI: left ventricular mass index 
TTE: trans-thoracic echocardiogram 
VAI: valvulo-arterial impedance 
  
 Introduction 
Aortic stenosis (AS) is the commonest valve lesion requiring surgery in the developed 
world with increasing prevalence with aging populations (1). Symptomatic severe AS is a 
malignant condition for which International guidelines recommend aortic valve replacement 
(AVR). The exact mechanisms leading to symptoms are uncertain and patients may remain 
asymptomatic for many years.  Considerable attention has focused on the role of left ventricular 
(LV) hypertrophy and other changes within the myocardium or “LV remodelling”. This is 
initially thought to be adaptive, with increased wall thickness leading to normalisation of the 
wall stress and preservation of cardiac output (2). However, this eventually becomes 
maladaptive, leading to reduced myocardial perfusion (3,4), interstitial and replacement fibrosis 
(5,6) and impaired diastolic function (7) and systolic heart failure (8). 
The remodelling response and the timing of symptom onset is highly variable. Various 
observational studies, mainly utilising trans-thoracic echocardiography (TTE) and cardiac 
catheterisation, have established differences in LV geometry and function between male and 
female patients with a similar degree of AS, with females demonstrating smaller, more 
concentrically thickened hearts, with ‘supernormal’ systolic function (9-11). Recent cardiac 
magnetic resonance (CMR) imaging studies have shown lower LV mass/volume in females 
(12,13). 
Genome-wide association studies have also identified sex-dependent differences, with a 
greater profibrotic and inflammatory response to pressure overload in men, but supressed extra-
cellular matrix remodelling and inflammatory gene pathways in female ventricles (14). Matrix 
metalloproteinases (MMP’s) and their tissue inhibitors (TIMP’s) have been implicated in 
pathological remodelling(15), progression to diastolic dysfunction(16)and heart failure in AS 
 (17). Additionally, Syndecan-1 and 4 are increasingly recognized to mediate pro-fibrotic 
signalling in cardiac fibroblasts (18). As sex differences in these markers have not previously 
been reported in AS, they were selected to reflect the likely differences in LV remodelling and 
myocardial fibrosis between sexes. 
The aims of this study were to assess whether:  differential LV remodelling in female and 
male patients with AS is associated with: 1. altered cardiac function and circulating biomarkers 
associated with myocardial fibrosis and 2. clinical outcomes in initially asymptomatic patients. 
Methods 
Subjects 
Asymptomatic patients with moderate to severe AS were recruited as part of the 
‘PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with AS’ 
(PRIMID-AS) study(19,20). The national research ethics service approved the study and written 
informed consent was obtained from all participants. 
Investigations 
TTE 
A comprehensive TTE was performed by an accredited sonographer according to 
International guidelines (21). All image analysis was conducted at the core lab by a single 
physiologist, using an Xcelera (Phillips, Best, The Netherlands) workstation, to assess AS 
severity, diastolic function, strain (using Speckle Tracking) and Valvulo-arterial impedance 
(VAI)(22). Blood pressure was measured on the same day at rest prior to performing the TTE. 
CMR 
Patients underwent comprehensive multi-parametric 3T CMR (including a stress and rest 
first-pass perfusion imaging, pre- and post-contrast T1 mapping and late gadolinium 
 enhancement (LGE) imaging after a total of 0.15 mmol/kg of gadolinium-based contrast agent) 
as previously described, at five sites within the UK(19). All image analysis was undertaken at the 
core lab by a single observer (AS), blinded to the patient data. Volumetric, T1 and LGE analysis 
was performed using cvi42 version-5 (Circle Cardiovascular Imaging, Calgary, Canada). 
Papillary muscles were excluded from the myocardial mass analysis. The presence or absence of 
late-gadolinium enhancement (LGE) was visually determined by two experienced observers 
(GPM/AS), and classified as ‘ischaemic’ or non-ischaemic’ distribution, and was quantified 
using >5SD above the mean signal intensity of normal myocardium(23). Extracellular volume 
(ECV) was calculated using Hct measured on the same day. We have previously shown excellent 
reproducibility of ECV calculation using dual-bolus contrast injection(24). Extracellular 
myocardial volume index (ECV× myocardial volume index) and myocyte volume index ([1-
ECV] × myocardial volume index) were calculated(25). Quantitative perfusion analysis was 
performed using Q-mass version-7.1(4). Diogenes Feature Tracking software (TomTec Imaging 
Systems, Munich, Germany) was used for strain analysis(26). Pulse wave velocity (PWV) was 
calculated using Jim (Version 6, Xinapse systems, UK). VAI was also calculated using CMR-
derived stroke volume (LVEDV-LVESV). 
Plasma Biomarkers 
Blood samples were collected in EDTA tubes and centrifuged within 4 hours at 2000g for 
20 minutes. Plasma was then drawn off and stored at -80°C. Biomarker analysis was performed 
in a batch with a Luminex® bead-based multiplex assay(27), using antibodies from R&D 
Systems (Minneapolis, MN, USA). Colour-coded beads were pre-coated with a capture antibody 
for MMP-2, 3, 7, 8, 9, 12, TIMP-1 and 4, Syndecan-1 and 4, and added to the wells containing 
the sample. R-Phycoerythrin (RPE) secondary antibodies were then incubated with the samples. 
 After washing, the beads were read on a Luminex Bio-Plex 3D Reader (Bio-Rad, Hercules, CA, 
USA) (see Supplemental document). NT-proBNP was analysed using our in-house non-
competitive assay that employs the quantitative sandwich enzyme immunoassay technique.  
Follow-up and primary endpoint 
Patients were followed up at 6-monthly intervals until a primary endpoint or end of study 
was reached. A primary endpoint was a composite of typical AS symptoms necessitating referral 
for AVR, cardiovascular death or major adverse cardiovascular events (hospitalisation with heart 
failure, chest pain, syncope or arrhythmia).  
Statistical analysis 
Baseline data was collected using electronic case-record forms, and blinded imaging data 
was sent to the Robertson Centre for Biostatistics, University of Glasgow, for unblinding and 
statistical analysis. Normally distributed data are expressed as mean±standard deviation.  Non-
parametric data are expressed as median[interquartile range]. Continuous variables were 
compared between male and female patients using independent t-tests or Mann-Whitney tests. 
The Chi-squared test or Fisher’s exact test were used for categorical variables. Linear regression 
analysis was performed to look at correlations with LVMI and LV mass/volume. Univariate and 
multivariate associates of the primary outcome were determined using Cox proportional hazards 
regression and stepwise selection. Variables for the stepwise models were selected based on 
statistical significance (p<0.05) and clinical relevance (based on previously determined 
associations), avoiding co-linear variables. 
Results 
Demographic and echocardiographic data 
 174 subjects (133 male, 41 female) were recruited (table-1). Male patients were slightly 
older, with larger BSA. There was no difference in resting haemodynamics, incidence of most 
co-morbidities and common cardiovascular medication use. Men had slightly higher AVA but 
not when indexed to body surface area (AVAI) and had similar pressure gradients.  . The septal 
E/e’ was higher in females, as was the longitudinal peak early diastolic strain rate (PEDSR) 
(Speckle Tracking unanalysable in 52 patients: 41 male, 11 female). Moderate aortic 
regurgitation was present in five patients and none had more than mild mitral regurgitation. The 
demographic and remodelling data in the severe AS sub-group were similar (Supplemental Table 
1). 
CMR data 
Male subjects had significantly higher indexed LV volumes and mass, more concentric 
remodelling (higher mass/volume ratio), and a lower systolic (LVEF, longitudinal and 
circumferential peak systolic strain) and diastolic (longitudinal and circumferential PEDSR) 
function than females(table-2, figure-1). Rest and stress MBF were significantly lower in males, 
with no difference in MPR, whilst PWV was significantly higher. The prevalence of LGE tended 
to be higher in male patients and extent of LGE was higher. There were 51 men and 11 women 
with non-infarct pattern LGE. There was no difference in native T1 but ECV was marginally 
higher in females but total extracellular myocardial volume and indexed extracellular myocardial 
volume were higher in males. 
Plasma Markers 
There was no significant difference in NT-proBNP levels between the sexes. Syndecan-4 
and MMP-3 levels were higher in males. Whilst MMP-3 correlated with several CMR markers, 
 after adjusting for sex, these did not reach statistical significance. Syndecan-4 however, was 
associated with increased ventricular volumes (LVEDV, LVESV and RVEDV). 
Associations with LVMI 
Table 4 shows univariate and multivariate associations of LVMI. Male sex was 
significantly associated with LVMI for the overall population and remained on multivariate 
analysis (β=12.10 (7.55-16.64), p<0.001). AV Vmax and MPG were associated with LVMI for 
both sexes, AVA or AVAI were not (figure-2). Whilst longitudinal strain parameters were 
associated with LVMI in both sexes, circumferential parameters and ejection fraction were only 
significant in males. NT-proBNP, left atrial volume index and markers of focal and diffuse 
fibrosis were associated with LVMI in male patients only. Serum biomarkers were not associated 
with LVMI. The following variables were entered into a stepwise multivariate model: age, 
VAI(CMR), AV Vmax, PWV, diabetes and BMI. AV Vmax was independently associated with 
LVMI in both sexes, whilst VAI and BMI was also associated in males. Univariate and 
multivariate associations of LV mass/volume are shown in Supplemental Table 2. 
Associations with primary outcome 
During median follow-up of 374 (IQR 351-498) days, 18 (43.9%) females developed 
symptoms (1 of whom died shortly after symptom onset), compared to 29 (21.8%) endpoints in 
males (28 symptom onset and 1 sudden death) (RR 0.50 (CI 0.31, 0.80), p=0.004). There were 
no other MACE endpoints. Measures of AS severity were associated with the primary outcome 
in both sexes, whereas NT-proBNP, MMP3 and mass/volume were only associated in males 
(table-5). The following variables were entered into the stepwise multivariate model: log10(NT-
proBNP), log10(MMP3), AV Vmax, VAI(CMR), LV mass/Volume, MPR, ECV and %LGE. On 
excluding ECV from the model, log10(NTpro-BNP) was significant for male patients instead. 
 Discussion 
This is the first study to show that significant sex differences in CMR-detected fibrosis 
are associated with plasma biomarkers of LV remodelling and fibrosis, in asymptomatic patients 
with AS. Male patients demonstrated more concentric remodelling, cardiac dysfunction and 
fibrosis than females, with biomarkers associated with remodelling/fibrosis being significantly 
higher. Despite this, there was a higher incidence of symptom onset in females. This uncoupling 
of LV remodelling and symptoms between genders, that has not been recognized previously, is 
likely to be important in clinical management and merits further attention. 
Remodelling 
Our finding of more concentric LV remodelling (higher mass/volume) in males is 
contrary to previous TTE studies showing higher relative wall thickness in females (10,28). 
However, TTE measurements are based on a single basal slice, usually using M-mode, which has 
many assumptions about the shape and symmetry of the LV. CMR overcomes many of these 
limitations and is now regarded as the gold standard for quantitative LV assessment (29,30). Two 
CMR studies have also shown higher LVMI(12,13) and LV mass/volume (12) in male AS 
patients and Dweck et al showed that male sex was associated with LVMI (31). 
Contrary to previous CMR studies (12,13), we saw a strong trend (p=0.06) towards less 
LGE in females. The likely reason for this apparent discrepancy is that in both previous studies, 
females had more severe AS and were also older in Dobson et al’s study. Our observation is 
unlikely to be spurious since females also demonstrated better function and lower levels of 
biomarkers associated with fibrosis. Previous histological studies have also confirmed that 
females have less myocardial fibrosis and lower collagen volume at the time of AVR (11). 
 Interestingly, ECV, which is widely regarded as a measure of diffuse interstitial fibrosis 
was higher in females than males.  There are 2 likely explanations for this apparent discrepant 
finding. Firstly, ECV is more than just a measure of diffuse interstitial fibrosis, as it measures all 
the extracellular space, including the normal matrix supporting myocytes as well as 
intramyocardial blood vessels, and given that hematocrit tends to be lower in females, this may 
contribute to the higher ECV. The healthy ECV is ~25%(32), whilst interstitial fibrosis is often 
very low (~6.5%)(33), so in early disease ECV vastly overestimates diffuse fibrosis. Secondly, 
the normal range in healthy females is typically higher than males (32), so this may just represent 
normal values. Future studies assessing ECV should adjust for gender in their population. 
Consistent with females having less interstitial fibrosis was the finding of reduced total extra-
cellular volume index. 
Biomarkers 
Syndecan-4, a cell surface proteoglycan that promotes collagen cross-linking, was 
associated with increased volumes, and may play an important role in LV remodelling. Increased 
levels of MMP3, which is a collagenase that breaks down collagen and basement membrane 
components, implies increased extracellular matrix turnover and remodelling, leading to collagen 
accumulation and fibrosis. This is the first study to report that MMP3 has sex-dependent 
expression differences in asymptomatic AS. Lower MMP3 in females has been found in other 
conditions including bacterial sepsis, stroke, and myocardial infarction (MI) (34,35) and it 
predicted LV dysfunction, remodelling and mortality after MI (36). Female sex steroids reduced 
collagen deposition 3 fold more than testosterone in human aortic smooth muscle cells, and 
testosterone increased gene and protein expression of MMP3 relative to both control and female 
sex steroids (37). In a mouse model of pressure overload, wild-type male mice developed 
 eccentric hypertrophy and more pronounced cardiac fibrosis, a difference that was abolished in 
oestrogen receptor-beta knockout mice (38). Given that MMP3 independently predicts the 
primary outcome in men only, and estradiol/progesterone is associated with reduced MMP3 
expression, circulating MMP3 may be central to understanding the sex differences in phenotype 
in AS. 
Collectively these data suggest that for a given degree of AS, females adapt with less 
concentric remodelling and less focal myocardial fibrosis, but still have a greater incidence of 
spontaneous symptom onset. There are several possible explanations for this seemingly counter-
intuitive finding.  Our main outcome measure was symptom onset, as we wanted to identify ‘pre-
symptomatic’ patients who may benefit from prophylactic AVR, which is quite distinct from 
previous studies that have correlated fibrosis and remodelling with adverse prognosis, mainly 
mortality, including post-AVR. Females were likely to have higher wall stress, due to less 
adaptive concentric remodelling for a given pressure gradient (Law of Laplace), which is 
supported by higher resting myocardial blood flow and numerically higher NT-proBNP levels, 
which may lead to earlier symptoms.  And although females had less focal fibrosis, they 
demonstrated higher LV filling pressure (higher septal E/e’ associated with a similar degree of 
atrial remodelling) that may limit the ability to further compensate with increasing AS severity. 
Another possibility is that females, particularly the elderly, tend to be less physically active (39) 
and there may be subjective differences in the interpretation and acknowledgement of symptoms. 
If symptom onset leads to earlier intervention, in combination with less irreversible 
fibrosis(40,41), this may also explain the better post-operative long-term survival in some female 
subgroups(42-44). 
Limitations 
 The number of female participants, and hence the number of endpoints reached, were 
relatively low, leading to limitations in statistical interpretation, particularly in multivariate 
analysis, and the findings should be confirmed in additional studies. Clinical outcome was, as 
expected, driven by symptom development and not hard clinical endpoints. However, symptoms 
heralds a rapid decline in prognosis and is an indication for AVR, so we feel this is a valid 
outcome measure. Although all fibrosis parameters tended to be higher in males than females, 
the difference for non-infarct LGE was not statistically significant.  We measured circulating 
biomarkers associated with myocardial fibrosis but we cannot be certain that there is no 
contribution from other tissues. 
Conclusions 
Asymptomatic male patients with moderate to severe AS demonstrate more concentric 
LV remodelling, a trend to more myocardial fibrosis (and increased plasma markers of fibrosis) 
and cardiac dysfunction than females.  However, there is dissociation between LV 
remodelling/fibrosis and symptom onset, which was more common in females, which requires 
further investigation. 
  
 Competency in medical knowledge 
This work enhances our understanding of the gender differences in remodelling and symptom 
onset in AS, and their associations with biomarkers. 
Translational outlook 
This study highlights the need for further studies to establish the reasons for differential 
remodelling and symptom onset between sexes, and perhaps explore if sex-specific definitions of 
AS severity may have a role in the future. 
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 Figure Legends 
 
Figure-1. An example of a male (top panel) and female (bottom panel) patient with similar 
degree of aortic stenosis.  
The figure shows the end-diastolic frame of a short-axis cine (a,e), and-systolic still of a 3-chamber 
cine (b,f), native T1 map (c,g) and late-gadolinium enhancement image (d,h) with insertion point 
non-infarct pattern LGE in the male patient (arrows). (Male: AVAI=0.41cm2/m2, LVEDVI=122 
ml/m2, LVMI=110g/m2, mass/vol=0.90; Female: AVAI=0.36cm2/m2, LVEDVI=71 ml/m2, 
LVMI=33g/m2, mass/vol=0.0.47) 
 
Figure-2. Relationship between left ventricular mass index and markers of AS severity in 
male and female patients. 
Positive correlation of LVMI with AV Vmax and MPG, and no correlation with AVAI. 
  
 Table 1. Demographic and echocardiographic data 
 All (n=174) Male (n=133) Female (n=41) p-value  
Demographic data 
Age (years) 66.2 ± 13.34 67.3 ± 12.64 62.9 ± 15.08 0.066 
BMI (kg/m2) 28.0 ± 4.15 28.0 ± 4.04 27.9 ± 4.53 0.826 
BSA (m2) 2.0 ± 0.21 2.0 ± 0.18 1.8 ± 0.17 <0.001* 
HR (bpm) 70.3 ± 11.43 70.0 ± 11.11 71.2 ± 12.50 0.561 
SBP (mmHg) 146.9 ± 21.09 148.2 ± 20.14 142.7 ± 23.70 0.146 
DBP (mmHg) 77.2 ± 10.65 78.0 ± 10.40 74.3 ± 11.06 0.049* 
Diabetes (n (%)) 25 (14.4) 21 (15.8) 4 (9.8) 0.336 
Hypertension (n (%)) 93 (53.4) 70 (52.6) 23 (56.1) 0.697 
Hyperlipidaemia (n (%)) 92 (52.9) 78 (58.6) 14 (34.1) 0.015* 
ACE-I/ARB (n (%)) 77 (44.3) 58 (43.6) 19 (46.3) 0.758 
Beta-blocker (n (%)) 54 (31.0) 39 (29.3) 15 (36.6) 0.380 
Statin 105 (60.3) 82 (61.7) 23 (56.1) 0.525 
Echocardiography data 
AV Vmax (m/s) 3.86 ± 0.56 3.83 ± 0.54 3.97 ± 0.61 0.154 
MPG (mmHg) 35.4 ± 12.49 34.5 ± 12.05 38.0 ± 13.66 0.121 
AVAI (cm2/m2) 0.57 ± 0.14 0.58 ± 0.14 0.55 ± 0.15 0.206 
AVA (cm2) 1.12 ± 0.31 1.16 ± 0.30 0.96 ± 0.28 <0.001* 
Severe AS (n(%)) 123 (70.7) 93 (69.9) 30 (73.2) 0.845 
E/A 0.88 ± 0.29 0.86 ± 0.26 0.96 ± 0.35 0.079 
Septal E/e’ 12.28 ± 4.86 11.71 ± 4.15 14.20 ± 6.43 0.029* 
Lateral E/e’ 9.88 ± 3.72 9.56 ± 3.43 10.94 ± 4.46 0.080 
VAI (mmHg/ml/m2) 3.96 ± 1.06 3.99 ± 1.08 3.86 ± 1.00 0.508 
Longitudinal PSS (%) -18.18 ± 2.76 -17.97 ± 2.79 -18.82 ± 2.58 0.140 
Longitudinal PEDSR (1/s) 0.79 ± 0.21 0.76 ± 0.19 0.86 ± 0.25 0.024* 
 
Abbreviations: BMI=body mass index, BSA=body surface area, HR=heart rate, SBP/DBP=systolic/diastolic blood pressure, ACE-
I=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, AV Vmax=peak aortic jet velocity, MPG=mean pressure 
gradient, AVAI=aortic valve area indexed to BSA, AS=aortic stenosis, DPT=diastolic perfusion time, VAI=valvulo-arterial impedance, 
PSS=peak systolic strain, PEDSR=peak early diastolic strain rate  
 
 
  
  
 Table 2. CMR data for male and female patients 
 Male (n=133) Female (n=41) p-value  
LVEDVI (ml/m2) 90.00 ± 18.67 79.74 ± 14.50 0.002* 
LVESVI (ml/m2) 39.97 ± 10.70 32.80 ± 8.49 <0.001* 
LVSVI (ml/m2) 50.04 ± 9.71 46.92 ± 7.48 0.061 
LVEF (%) 55.9 ± 4.84 59.2 ± 4.49 <0.001* 
LVMI (g/m2) 60.54 ± 13.70 48.45 ± 9.74 <0.001* 
LV mass/volume (g/ml) 0.68 ± 0.11 0.61 ± 0.11 0.001* 
Myocyte volume index (ml/m2) 42.28 [36.9. 48.2] 32.77 [30.6, 39.1] <0.001* 
Extracellular volume index (ml/m2) 13.27 [11.5, 17.0] 11.53 [10.5, 13.5] 0.017* 
LAVI (ml/m2) 54.81 ± 14.43 55.46 ± 15.98 0.807 
RVEDVI (ml/m2) 91.26 ± 14.48 78.39 ± 13.07 <0.001* 
VAI (mmHg/ml/m2) 3.77 ± 0.81 3.95 ± 0.86 0.231 
PWV (m/s) 8.76 ± 3.73 7.25 ± 2.71 0.005* 
Stress MBF (ml/min/g) 2.09 ± 0.66 2.39 ± 0.80 0.020* 
Rest MBF (ml/min/g) 0.93 ± 0.21 1.14 ± 0.36 0.002* 
MPR 2.29 ± 0.70 2.18 ± 0.70 0.380 
LGE present (n,%) 68 (51.1) 14 (34.1) 0.057 
Non-infarct LGE (n,%) 51 (38.3) 11 (26.8) 0.178 
LGE (g) 3.39 [10.6, 6.9] 0.95 [0.44, 2.7] <0.001* 
% LGE (%) 3.70 [1.03, 7.00] 1.60 [0.65, 4.30] 0.007* 
Native T1 (ms) 1137.2 ± 71.06 1115.3 ± 62.73 0.139 
ECV (%) 24.57 ± 2.54 25.64 ± 1.85 0.044* 
Longitudinal PSS (%) -17.85 ± 2.80 -20.52 ± 2.81 <0.001* 
Longitudinal PEDSR (1/s) 1.04 ± 0.27 1.25 ± 0.26 0.030* 
Circumferential PSS (%) -27.64 ± 4.83 -29.56 ± 3.74 0.021* 
Circumferential PEDSR (1/s) 1.60 ± 0.39 1.91 ± 0.36 <0.001* 
 
Abbreviations: As in Table-1 and LVEDVI=left ventricular end-diastolic volume indexed to BSA, LVESVI=left ventricular end systolic volume 
indexed to BSA, LVSVI=left ventricular stroke volume indexed to BSA, LVEF=left ventricular ejection fraction, LVMI=left ventricular mass 
indexed to BSA, LAVI=left atrial volume indexed to BSA, RVEDVI=right ventricular end diastolic volume indexed to BSA, PWV=pulse wave 
velocity, MPR=myocardial perfusion reserve, MBF=myocardial blood flow, LGE=late gadolinium enhancement, ECV=extracellular volume  
 
  
 Table 3. Plasma biomarker data for male and female patients 
 
Male (n=33) Female (n=41) p-value 
MMP 2 (ng/mL) 806 [503, 3615] 731 [469, 2230] 0.471 
MMP 3 (ng/mL)  26.1 [15.3, 114.8]  17.6 [9.3, 46.8] 0.041* 
MMP 7 (pg/mL)    823 [396, 1379]    735 [415, 1701] 0.638 
MMP 8 (ng/mL)   2.28 [0.02, 5.66]   1.49 [0.02, 5.34] 0.659 
MMP 9 (ng/mL)  93.9 [41.8, 214] 141 [59.6, 269] 0.429 
MMP 12 (pg/mL)     67.8 [4.15, 117]     38.4 [4.15, 107] 0.842 
TIMP 1 (ng/mL) 392 [269, 531] 344 [205, 519] 0.208 
TIMP 4 (ng/mL)   3.8 [0.75, 379.7]   1.9 [0.51, 379.7] 0.116 
Syndecan 1 (pg/mL)    185 [102, 319]    170 [73.1, 287] 0.464 
Syndecan 4 (pg/mL)    213 [84.8, 449]    141 [1.07, 260] 0.043* 
NT-proBNP (pg/mL)     53.8 [17.4, 144]     73.4 [22.7, 243] 0.165 
 
Results expressed as median [IQR]. MMP=Matrix Metalloproteinase, TIMP=Tissue Inhibitor of Matrix Metalloproteinase, NT-proBNP=N 
terminal brain natriuretic peptide   
 Table 4. Univariate and multivariate associations with LVMI in male and female 
patients 
Variable Male Female 
 Estimate (95% CI) p-value Estimate (95% CI) p-value 
Age -0.18 (-0.37, 0.00) 0.053 -0.21 (-0.40, -0.01) 0.042 
Log(NTproBNP) 1.83 (0.55, 3.10) 0.005 0.07 (-1.65, 1.79) 0.932 
AV Vmax 10.98 (7.03, 14.93) <0.001 7.30 (2.72, 11.88) 0.003 
MPG 0.48 (0.31, 0.66) <0.001 0.32 (0.11, 0.52) 0.004 
AVAI 0.45 (-16.9, 17.77) 0.959 12.99(-7.62, 33.60) 0.210 
Septal E/e’ -0.18 (-0.76, 0.40) 0.540 -0.65 (-1.45, 0.14) 0.106 
Lateral E/e’ -0.18 (-0.94, 0.59) 0.651 -0.19 (-1.23, 0.85) 0.714 
VAI (CMR) -4.91 (-7.72, -2.10) 0.001 -2.55 (-6.14, 1.05) 0.160 
PWV 0.05 (-0.62, 0.71) 0.892 -0.84 (-2.00, 0.33) 0.154 
LAVI 0.20 (0.04, 0.36) 0.017 0.01 (-0.19, 0.21) 0.932 
LVEF -0.83 (-1.30, -0.36) 0.001 -0.44 (-1.13, 0.25) 0.204 
Rest MBF -3.10 (-14.4, 8.20) 0.588 -8.23 (-15.3, -1.15) 0.024 
Stress MBF -3.28 (-6.97, 0.41) 0.081 -2.74 (-6.06, 0.59) 0.103 
MPR -2.83 (-6.30, 0.64) 0.109 -0.45 (-4.42, 3.51) 0.818 
LGE presence 4.98 (0.34, 9.62) 0.036 -1.80 (-8.35, 4.74) 0.581 
LGE % 0.56 (-0.06, 1.17) 0.075 -0.44 (-1.47, 0.60) 0.398 
Native T1 0.06 (0.02, 0.10) 0.003 0.03 (-0.03, 0.10) 0.293 
ECV 1.23 (0.05, 2.42) 0.042 -0.67 (-2.98, 1.64) 0.556 
PSS-L (CMR) 1.21 (0.38, 2.03) 0.004 1.18 (0.13, 2.24) 0.029 
PEDSR-L (CMR) -18.2 (-26.6, -9.86) <0.001 -14.7 (-26.0, -3.47) 0.012 
PSS-C (CMR) 0.55 (0.06, 1.03) 0.027 0.05 (-0.80, 0.89) 0.913 
PEDSR-C (CMR) -10.4 (-16.2, -4.56) 0.001 -1.30 (-10.10, 7.48) 0.766 
Log10 MMP3 2.08 (-1.36, 5.53) 0.234 -1.58 (-5.26, 2.09) 0.390 
Log10 Syndecan4 1.53 (-0.30, 3.36) 0.100 0.46 (-1.98, 2.91) 0.702 
Multivariate associations:- 
VAI (CMR) -6.92 (-9.26, -4.59) <0.001   
AV Vmax 14.35 (10.78, 17.92) <0.001 7.31 (2.81, 11.81) 0.003 
BMI 0.98 (0.51, 1.46) <0.001   
 
Abbreviations: As Table-1 and 2. Stepwise multivariate analysis after entering the following variables: age, VAI (CMR), AV Vmax, PWV, 
diabetes and BMI.  
  
Table 5. Univariate and multivariate associations with the primary outcome in male 
and female patients 
Variable Male Female 
 HR (95% CI) p-value HR (95% CI) p-value 
Age 1.04 (1.00, 1.09) 0.072 1.01 (0.97, 1.04) 0.695 
Log(NTproBNP) 1.46 (1.08, 1.98) 0.015 1.19 (0.88, 1.61) 0.264 
AV Vmax 3.78 (1.86, 7.69) <0.001 2.68 (1.21, 5.93) 0.015 
MPG 1.06 (1.03, 1.09) <0.001 1.04 (1.01, 1.08) 0.010 
AVAI 0.00 (0.00, 0.17) 0.003 0.01 (0.00, 0.59) 0.027 
VAI (CMR) 1.41 (0.86, 2.31) 0.175 1.52 (0.88, 2.65) 0.134 
LVMI 1.01 (0.98, 1.04) 0.374 1.02 (0.97, 1.07) 0.511 
LV mass / Volume 105.7 (4.01, 2784) 0.005 2.70 (0.03, 232.4) 0.662 
LVEDVI 0.99 (0.96, 1.01) 0.309 1.00 (0.97, 1.04) 0.815 
LAVI 1.03 (1.00, 1.06) 0.059 1.00 (0.98, 1.03) 0.793 
LVEF 1.05 (0.96, 1.15) 0.251 0.94 (0.84, 1.05) 0.276 
MPR 0.65 (0.34, 1.24) 0.189 0.51 (0.24, 1.11) 0.092 
Stress MBF 0.51 (0.24, 1.09) 0.083 0.84 (0.45, 1.57) 0.574 
Rest MBF 0.67 (0.09, 5.20) 0.704 2.57 (0.87, 7.61) 0.087 
LGE presence 1.55 (0.66, 3.62) 0.316 0.77 (0.27, 2.18) 0.617 
LGE % 1.01 (0.91, 1.12) 0.863 1.00 (0.85, 1.17) 1.000 
Native T1 1.00 (0.99, 1.01) 0.714 1.00 (0.99, 1.01) 0.751 
ECV 1.19 (0.99, 1.44) 0.069 0.91 (0.67, 1.23) 0.536 
PSS-L 1.01 (0.87, 1.17) 0.931 1.15 (0.95, 1.39) 0.147 
PEDSR-L 1.58 (0.34, 7.38) 0.563 0.85 (0.12, 5.81) 0.866 
PSS-C 0.91 (0.83, 1.01) 0.066 1.00 (0.87, 1.14) 0.962 
PEDSR-C 1.74 (0.61, 4.97) 0.303 0.95 (0.25, 3.62) 0.935 
Log10 MMP3 1.84 (1.04, 3.28) 0.037 1.25 (0.69, 2.27) 0.459 
Log10 Syndecan 4 0.97 (0.71, 1.34) 0.852 1.1 (0.75, 1.61) 0.617 
Multivariate associations:- 
AV Vmax 5.29 (2.21, 12.67) <0.001 3.09 (1.18, 8.06) 0.022 
ECV 1.27 (1.03, 1.57) 0.026   
Log10 MMP 3 3.33 (1.54, 7.21) 0.002   
 
 Abbreviations: As Table-1 and 2. Stepwise multivariate analysis after entering the following variables: log(NT-proBNP), AV Vmax, VAI 
(CMR), LV mass/Volume, MPR, ECV and %LGE. On excluding ECV from model, log(NTpro-BNP) and AV Vmax are independently associated 
with the primary outcome for male patients andAV Vmax remains for females. 
